Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1023 - Real-World Everolimus Experience in Postmenopausal HR+ HER2- Advanced Breast Cancer Women – Treat ER+ight Canadian Prospective Observational Study 2nd Subgroup Analysis

Date

11 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Breast Cancer

Presenters

Catherine Doyle

Citation

Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365

Authors

C. Doyle1, N. Califaretti2, S. Dent3, E. Chouinard4, S.R. Perri5, S. Chia6

Author affiliations

  • 1 Oncology, Centre des Maladies du Sein Deschênes-Fabia, G1S 4L8 - Quebec/CA
  • 2 Medical Oncology, Grand River Regional Cancer Center, Kitchener/CA
  • 3 Medical Oncology, Ottawa Hospital Cancer Center, K1H 8L6 - Ottawa/CA
  • 4 Oncology, Cambridge Memorial Hospital, Cambridge/CA
  • 5 Medical Affairs, Novartis Pharmaceuticals Canada Inc., H9S1A9 - Dorval/CA
  • 6 Medical Oncology, BC Cancer Agency - Vancouver Cancer Center, Vancouver/CA
More

Resources

Abstract 1023

Background

Treat ER+ight is the 1st Canadian real-world study enrolling patients (pts) previously exposed to letrozole or anastrozole and currently receiving endocrine therapy (ET) alone or in combination with targeted therapy.

Methods

At data cut-off (13 Mar '17), 35 pts were enrolled in the everolimus + exemestane (EVE+EXE) subgroup out of 100 total enrolled pts since Mar '16 from 24 active sites. This sub-analysis describes baseline characteristics, treatment duration and stomatitis prevention outcomes in EVE+EXE pts.

Results

Baseline characteristics: median age – 65 (39-80); family history of breast cancer (BC) – 37%; ECOG 0-1 – 83%; median time since primary BC diagnosis – 6 yrs (2-12); median time since advanced BC diagnosis – 1 yr (0-3.5). Sites of metastases (%): bone (B) only – 26; visceral (V) only – 43; B+V – 23. Line (L) of metastatic therapy (%): 17 - 1L, 51 - 2L, 31 - 3L. EVE start dose (%): 10mg (80), 7.5mg (3), 5mg (17). Therapy ongoing n (%): 23 (66) (78% 1L & 2L). Therapy discontinued n (%): 12 (34) (50% 3L). Reason for discontinuation n (%): 9 (75) progression, 2 (17) adverse event, 1 (8) death. Median follow-up time at data cut-off 3.4 mths (0.5-9.1). Median time to treatment discontinuation (TTD) 7.0 mths (95% CI, 3.4-NR) in overall subgroup. Median TTD NR (95% CI, 2.4-NR) in 20 (57%) pts receiving prophylactic/proactive mouthwash (P/P MW) compared to 5.7 mths (95% CI, 3.2-NR) in 15 (43%) pts receiving reactive/no MW (p = 0.140, Log-rank). 1st stomatitis event related to EVE n (%): overall subgroup 10 (29) – any Grade (Gr), 7 (20) – Gr 1, 2 (6) – Gr 2, 1 (3) – Gr 3 and in P/P MW subgroup 3 (15) – any Gr. Median time to 1st stomatitis event in P/P MW subgroup (mths) NR (95% CI, 1.64-NR) and NR (95% CI, 0.33-NR) in reactive/no MW subgroup (p = 0.334, Log-rank) with majority of stomatitis events occurring early within the 1st 2 months of therapy.

Conclusions

Compared to BOLERO-2, EVE+EXE pts in Treat ER+ight had lower ECOG 0-1 (83 vs 96%), more V disease (66 vs 56%), 20% received lower EVE start dose, similar treatment duration (7.0 mths median TTD vs 7.8 mths median PFS) and lower any Gr stomatitis (29 vs 59%). This represents the 1st observation of a trend toward improved TTD in pts receiving P/P MW upon EVE initiation.

Clinical trial identification

NCT02753686

Legal entity responsible for the study

Novartis Pharmaceuticals Canada Inc.

Funding

Novartis Pharmaceuticals Canada Inc.

Disclosure

E. Chouinard: Research support received from Novartis. S.R. Perri: Employee of Novartis Pharmaceuticals Canada Inc. S. Chia: Honorarium from Novartis and Pfizer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.